

Publications for Timothy Price

2017

Chan, D., Sjoquist, K., Goldstein, D., Price, T., Martin, A., Bang, Y., Kang, Y., Pavlakis, N. (2017). The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. *PLoS One*, 12(2), 1-16. [More Information]

Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. *New England Journal of Medicine*, 359(17), 1757-1765. [More Information]

2016

Chandrasegaram, M., Chen, J., Price, T., Zalcborg, J., Sjoquist, K., Merrett, N. (2016). Advances in Molecular Pathology and Treatment of Periampullary Cancers. *Pancreas*, 45(1), 32-39. [More Information]

Thavaneswaran, S., Price, T. (2016). Optimal therapy for resectable rectal cancer. *Expert Review of Anticancer Therapy*, 16(3), 285-302. [More Information]

2012

Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. *Annals of Oncology*, 23(6), 1531-1536. [More Information]

Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. *Expert Review of Gastroenterology and Hepatology*, 6(2), 199-209. [More Information]

2011

Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology*, 22(8), 1834-1838. [More Information]

2010

Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. *Internal Medicine Journal*, 40(6), 453-458. [More Information]

2008

Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C.,